GSK (GSK) said Wednesday it has started negotiations with the pan-Canadian Pharmaceutical Alliance for the use of Blenrep to treat adults with relapsed or refractory multiple myeloma, a type of blood cancer.
The talks cover the use of Blenrep plus bortezomib and dexamethasone, or combined with pomalidomide and dexamethasone, the company said.
Price: $50.97, Change: $-0.08, Percent Change: -0.16%
Roblox (RBLX) said Tuesday that its board has authorized a repurchase program of up to $3 billion of its common stock, with the intent to buy back up to $1 billion of stock over the next 12 months.This represents the company's first-ever share repurchase program, according to a statement.Shares of the company were up 4% in after-hours trading.
Relay Therapeutics (RLAY) launched an underwritten public offering of $175 million of common stock.Underwriters are set to receive a 30-day option to buy up to an additional 15% of the offering, the company said Tuesday in a statement.Relay shares fell 4.1% in after-hours trading.
Keysight Technologies (KEYS) reported fiscal Q2 non-GAAP net income late Tuesday of $2.87 per diluted share, up from $1.70 a year earlier.Analysts polled by FactSet expected $2.32.Revenue for quarter ended April 30 rose to $1.72 billion from $1.31 billion a year earlier.Analysts surveyed by FactSet expected $1.71 billion.The company expects fiscal Q3 non-GAAP EPS of $2.43 to $2.49 on revenue of $1.73 billion to $1.75 billion. Analysts expect $2.16 and $1.65 billion, respectively.Shares of Keysight Technologies were up almost 9% in after-hours activity.